Ultragenyx Pharmaceutical Inc. $RARE Shares Sold by Hennion & Walsh Asset Management Inc.

Hennion & Walsh Asset Management Inc. lowered its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 57.8% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 25,456 shares of the biopharmaceutical company’s stock after selling 34,852 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Ultragenyx Pharmaceutical were worth $850,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Parallel Advisors LLC boosted its stake in shares of Ultragenyx Pharmaceutical by 778.4% in the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,440 shares during the last quarter. Leonteq Securities AG lifted its holdings in Ultragenyx Pharmaceutical by 288.5% in the first quarter. Leonteq Securities AG now owns 1,795 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,333 shares during the period. Versant Capital Management Inc lifted its holdings in Ultragenyx Pharmaceutical by 662.9% in the second quarter. Versant Capital Management Inc now owns 1,152 shares of the biopharmaceutical company’s stock valued at $38,000 after acquiring an additional 1,001 shares during the period. Danske Bank A S purchased a new stake in Ultragenyx Pharmaceutical in the 3rd quarter worth approximately $39,000. Finally, EverSource Wealth Advisors LLC boosted its position in Ultragenyx Pharmaceutical by 573.0% in the 1st quarter. EverSource Wealth Advisors LLC now owns 2,167 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 1,845 shares in the last quarter. Institutional investors and hedge funds own 97.67% of the company’s stock.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $50 price target for Ultragenyx, implying substantial upside from recent trading levels. Ultragenyx Pharmaceutical Earns Buy Rating from HC Wainwright
• Positive Sentiment: The firm sharply raised its Q3 2026 EPS forecast to $0.75 from a projected loss of $0.84 and increased Q4 2026 EPS to $0.78 from a loss of $0.35. Its FY2026 loss estimate also improved to $1.18 per share from $4.27, suggesting stronger near-term profitability expectations.
• Neutral Sentiment: Analyst price targets compiled by brokerages were reported at an average of $57.82, although the article did not identify a specific change in the broader consensus. Brokerages Set Ultragenyx Pharmaceutical Price Target
• Negative Sentiment: HC Wainwright reduced its FY2027 EPS forecast to $4.50 from $5.61. Quarterly estimates were also cut for Q1 2027, to $0.06 from $0.27; Q2 2027, to $0.91 from $1.18; Q3 2027, to $1.25 from $1.54; and Q4 2027, to $2.27 from $2.63. These revisions signal slower expected earnings growth beyond 2026 and likely explain the cautious stock reaction.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on RARE shares. Wedbush dropped their target price on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. Morgan Stanley increased their price target on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an “overweight” rating in a research report on Thursday, April 16th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Monday. Guggenheim reduced their target price on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating for the company in a research note on Tuesday, August 4th. Finally, Wells Fargo & Company decreased their target price on Ultragenyx Pharmaceutical from $47.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $57.82.

Insider Buying and Selling at Ultragenyx Pharmaceutical

In related news, EVP Karah Herdman Parschauer sold 1,899 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the completion of the transaction, the executive vice president owned 94,462 shares in the company, valued at $2,325,654.44. The trade was a 1.97% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Howard Horn sold 4,653 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $23.77, for a total transaction of $110,601.81. Following the transaction, the chief financial officer owned 105,689 shares of the company’s stock, valued at approximately $2,512,227.53. The trade was a 4.22% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 14,292 shares of company stock worth $351,644. 5.20% of the stock is currently owned by corporate insiders.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE stock opened at $26.38 on Friday. The company has a market capitalization of $2.60 billion, a PE ratio of -4.52 and a beta of 0.35. The firm’s 50-day moving average is $28.22 and its two-hundred day moving average is $24.91. Ultragenyx Pharmaceutical Inc. has a 12 month low of $18.29 and a 12 month high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The firm had revenue of $214.00 million for the quarter, compared to analyst estimates of $183.08 million. During the same period in the previous year, the firm earned ($1.17) EPS. Ultragenyx Pharmaceutical’s revenue was up 28.5% on a year-over-year basis. Sell-side analysts forecast that Ultragenyx Pharmaceutical Inc. will post -4.08 EPS for the current year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.